Skip to main content

Log In Create an account

Products & Services
Back
Explore
- About Our Products & Services
- Our Tests
  Back
  Our Tests
  
  Compare Our Tests
  
  FoundationOne CDx
  
  FoundationOne Liquid CDx
  
  FoundationOne Heme
  
  IHC Testing
- Provider Services
  Back
  Provider Services
  
  Overview
  
  Online Ordering & Report Integrations
  
  Clinical Research & Trial Matching
  
  Decision Support
- Biopharma Partner Services
  Back
  Biopharma Partner Services
  
  Overview
  
  Genomic Data Solutions
  
  Clinical Trial Solutions
  
  Companion Diagnostic Development & Commercialization
- Actionable Results
Latest CDx Indication

FoundationOne®Liquid CDx, the broadest FDA-approved liquid biopsy, is now the only blood-based comprehensive genomic profiling companion diagnostic (CDx) for Lynparza® (olaparib) in prostate cancer.
Resource Center
Back
Explore
- View All Resources
- For Providers
  Back
  Provider FAQ
  
  What is Comprehensive Genomic Profiling?
  
  Which genes are tested?
  
  How do I order a Foundation Medicine test?
  
  View all Provider FAQs
  
  Provider Resources
  
  Why Comprehensive Genomic Profiling?
  
  Immunotherapy Biomarkers
  
  Billing and Financial Assistance
  
  View all Provider Resources
- For Biopharma Partners
  Back
  Biopharma Partner FAQ
  
  How can genomic data generated by Foundation Medicine tests be used for biomarker discovery?
  
  How can working with Foundation Medicine help facilitate drug development?
  
  How do I contact someone in the biopharma group to discuss a project?
  
  View all Biopharma Partner FAQs
  
  Biopharma Resources
  
  Biopharma Partner Services
  
  Biopharma Brochure
  
  View all Biopharma Resources
- For Patients
  Back
  Patient FAQs
  
  Do all test results lead to actionable treatment options?
  
  Does insurance cover my test?
  
  Do the tests apply to all types of cancer?
  
  View all Patient FAQs
  
  Patient Resources
  
  Patient Brochure
  
  Doctor Discussion Guide
  
  Financial Assistance Application
  
  View all Patient Resources
Latest CDx Indication

FoundationOne®Liquid CDx, the broadest FDA-approved liquid biopsy, is now the only blood-based comprehensive genomic profiling companion diagnostic (CDx) for Lynparza® (olaparib) in prostate cancer.
News & Events
Back
Explore
Useful Information
About Us
Back
About Us
Useful Information
Careers
For Patients
Order a Test

Blog

View

News & Events Overview
Press Releases
Blog
Events
Media Library

Products & Services
Our Tests
Provider Services
Biopharma Partner Services

News & Events
Press Releases
Blog
Events

About Us
Our Story
Leadership Team
Careers

Contact Us
Login
Order a Test

© 2021 FOUNDATION MEDICINE, INC.

Legal & Privacy
California Compliance
Licenses